332 related articles for article (PubMed ID: 24323900)
1. Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor.
ten Hacken E; Burger JA
Clin Cancer Res; 2014 Feb; 20(3):548-56. PubMed ID: 24323900
[TBL] [Abstract][Full Text] [Related]
2. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.
Ten Hacken E; Burger JA
Biochim Biophys Acta; 2016 Mar; 1863(3):401-413. PubMed ID: 26193078
[TBL] [Abstract][Full Text] [Related]
3. Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies.
ten Hacken E; Burger JA
Pharmacol Ther; 2014 Dec; 144(3):338-48. PubMed ID: 25050922
[TBL] [Abstract][Full Text] [Related]
4. Chronic Lymphocytic Leukemia: Disease Biology.
Koehrer S; Burger JA
Acta Haematol; 2024; 147(1):8-21. PubMed ID: 37717577
[TBL] [Abstract][Full Text] [Related]
5. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
Till KJ; Pettitt AR; Slupsky JR
J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
[TBL] [Abstract][Full Text] [Related]
6. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies.
Burger JA; Gribben JG
Semin Cancer Biol; 2014 Feb; 24():71-81. PubMed ID: 24018164
[TBL] [Abstract][Full Text] [Related]
7. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
Robak T; Robak P
Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
[TBL] [Abstract][Full Text] [Related]
8. B cell receptor signaling in chronic lymphocytic leukemia.
Burger JA; Chiorazzi N
Trends Immunol; 2013 Dec; 34(12):592-601. PubMed ID: 23928062
[TBL] [Abstract][Full Text] [Related]
9. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape.
Burger JA
Curr Opin Oncol; 2012 Nov; 24(6):643-9. PubMed ID: 22960555
[TBL] [Abstract][Full Text] [Related]
10. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Wiestner A
Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
[TBL] [Abstract][Full Text] [Related]
12. The chronic lymphocytic leukemia microenvironment: Beyond the B-cell receptor.
Choi MY; Kashyap MK; Kumar D
Best Pract Res Clin Haematol; 2016 Mar; 29(1):40-53. PubMed ID: 27742071
[TBL] [Abstract][Full Text] [Related]
13. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia.
Burger JA
Hematology Am Soc Hematol Educ Program; 2011; 2011():96-103. PubMed ID: 22160019
[TBL] [Abstract][Full Text] [Related]
14. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
15. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
[TBL] [Abstract][Full Text] [Related]
16. Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects.
Eiken AP; Smith AL; Skupa SA; Schmitz E; Rana S; Singh S; Kumar S; Mallareddy JR; de Cubas AA; Krishna A; Kalluchi A; Rowley MJ; D'Angelo CR; Lunning MA; Bociek RG; Vose JM; Natarajan A; El-Gamal D
Cancer Res Commun; 2024 May; 4(5):1328-1343. PubMed ID: 38687198
[TBL] [Abstract][Full Text] [Related]
17. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.
Herishanu Y; Pérez-Galán P; Liu D; Biancotto A; Pittaluga S; Vire B; Gibellini F; Njuguna N; Lee E; Stennett L; Raghavachari N; Liu P; McCoy JP; Raffeld M; Stetler-Stevenson M; Yuan C; Sherry R; Arthur DC; Maric I; White T; Marti GE; Munson P; Wilson WH; Wiestner A
Blood; 2011 Jan; 117(2):563-74. PubMed ID: 20940416
[TBL] [Abstract][Full Text] [Related]
18. Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia.
Ten Hacken E; Sivina M; Kim E; O'Brien S; Wierda WG; Ferrajoli A; Estrov Z; Keating MJ; Oellerich T; Scielzo C; Ghia P; Caligaris-Cappio F; Burger JA
J Immunol; 2016 Sep; 197(6):2522-31. PubMed ID: 27534555
[TBL] [Abstract][Full Text] [Related]
19. BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma.
Wiestner A
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):125-34. PubMed ID: 25696845
[TBL] [Abstract][Full Text] [Related]
20. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.
Quiroga MP; Balakrishnan K; Kurtova AV; Sivina M; Keating MJ; Wierda WG; Gandhi V; Burger JA
Blood; 2009 Jul; 114(5):1029-37. PubMed ID: 19491390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
